APA (7th ed.) Citation

BM, S., SJ, W., W, D., HS, C., V, P., MT, J. V., . . . DM, G. (2026). Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(3), 153. https://doi.org/10.1200/JCO-25-01348

Chicago Style (17th ed.) Citation

BM, Slomovitz, et al. "Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 3 (2026): 153. https://doi.org/10.1200/JCO-25-01348.

MLA (9th ed.) Citation

BM, Slomovitz, et al. "Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 3, 2026, p. 153, https://doi.org/10.1200/JCO-25-01348.